Omri Amirav-Drory founded biotech tools company Genome Compiler before it was acquired by Twist Bioscience, where he served as VP of Corporate Development and Innovation, giving him hands-on experience across the full TechBio lifecycle from lab tools to strategic corporate innovation. Beyond his GP role at NFX Bio, he has stepped in as acting CEO for highly futuristic TechBio ventures during incubation, bringing a company builder mindset that alternates between investor and operating leader inside very early TechBio concepts.

• Belief in the critical intersection of biology and artificial intelligence as the driver of future innovation. He frequently argues that the ultimate utility of advanced computing power lies in scientific discovery and curing diseases rather than consumer applications like chatbots.
• A strong investment focus on longevity and the extension of human healthspan. He regards this field as a personal favorite, consistently highlighting startups working to improve quality of life during aging and treating the root causes of age-related decline.
• Dedication to women's health, particularly where it overlaps with longevity and underserved medical conditions. He points out that while women statistically live longer, they often spend more years in poor health, creating a need for solutions addressing specific areas like ovarian aging, menopause, and endometriosis.
• Emphasis on operational speed and creativity for biotech startups trying to reach clinical trials. He champions methods that reduce time and cost, such as utilizing global trial locations, leveraging automation to run thousands of experiments overnight, and structuring teams to move faster than traditional pharmaceutical timelines.
• Tactical advice on the fundraising process, specifically regarding the timing and format of pitches. He stresses that founders should prioritize in-person meetings over video calls to build rapport and urges them to plan their raises around the natural seasonality of the venture capital industry to maximize success.